SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (363)12/21/1999 9:17:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1834
 
>> Some early criticisms of Lyons were that he had the company spread too thin on too many projects. <<

I was complaining, here at SI, and probably in this thread. However, it's worked out perfectly..... everyone bailed and left them dead in the water after the lame projects had trouble, and now they're focused on good stuff, all cylinders firing. This Spring was just like December of '94.



To: Biotech Jim who wrote (363)12/21/1999 10:50:00 PM
From: Steve Johnston  Respond to of 1834
 
Don't make too much of this deal. They spun off unwanted product assets to a small, Canadian venture healthcare company, in need of products and "news" as they wait to gain listing on Toronto, and sell off their closely held insider shares. Two million in cash, for the divested products, is but a "pimple on the ass" when it comes to NBIX's future success. Regards.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News